Table 1.

Clinical trials exploiting p38 inhibitors in cancer.

Study	Agent	Secondary Agent(s)	Target	Disease	Phase	Status
NCT01463631	LY3007113	N/A	p38	Metastatic cancer	I	Completed
NCT02364206	LY2228820	TMZ, Radiotherapy	p38	Glioblastoma	II	Active
NCT01663857	LY2228820	Carboplatin, Gemcitabine	p38	Ovarian cancer	II	Active
NCT02322853	LY2228820	Tamoxifen	p38	Breast cancer	II	Terminated
NCT01393990	LY2228820	N/A	p38	Advanced cancer	I	Completed
NCT02860780	LY2228820	Prexasertib	p38	Colorectal cancer, NSCLC	I	Completed
NCT00095680	SCIO-469	Bortezomib	p38	Multiple Myeloma	II	Completed
NCT00087867	SCIO-469	Bortezomib	p38	Multiple Myeloma	II	Completed
NCT00113893	SCIO-469	N/A	p38	Myelodysplastic syndrome	II	Completed
NCT01496495	ARRY-614	N/A	p38/Tie2	Myelodysplastic syndrome	I	Completed
NCT00916227	ARRY-614	N/A	p38/Tie2	Myelodysplastic syndrome	I	Completed